Neuroblastomas are characterized by 1p deletions, suggesting that a tumor suppressor gene (TSG) resides in this region. We have mapped the smallest region of deletion (SRD) to a 2 Mb region of 1p36.31 using microsatellite and single nucleotide polymorphisms. We have identified 23 genes in this region, and we have analysed these genes for mutations and RNA expression patterns to identify candidate TSGs. We sequenced the coding exons of these genes in 30 neuroblastoma cell lines. Although rare mutations were found in 10 of the 23 genes, none showed a pattern of genetic change consistent with homozygous inactivation. We examined the expression of these 23 genes in 20 neuroblastoma cell lines, and most showed readily detectable expression, and no correlation with 1p deletion. However, 7 genes showed uniformly low expression in the lines, and 2 genes (CHD5, RNF207) had virtually absent expression, consistent with the expected pattern for a TSG. Our mutation and expression analysis in neuroblastoma cell lines, combined with expression analysis in normal tissues, putative function and prior implication in neuroblastoma pathogenesis, suggests that the most promising TSG deleted from the 1p36 SRD is CHD5, but TNFRSF25, CAMTA1 and AJAP1 are also viable candidates.
Introduction
Neuroblastoma, a common and deadly tumor derived from the sympathetic nervous system, accounts for 8-10% of cancers and 15% of deaths from cancer in childhood (Brodeur and Maris, 2006) . However, neuroblastomas demonstrate heterogeneous clinical behavior, from spontaneous regression to relentless progression. This clinical heterogeneity is matched by different patterns of genetic change and gene expression that characterize these tumors into low-, intermediate-and high-risk subsets (Brodeur, 2003; Wang et al., 2006) .
Deletion of the short arm of chromosome 1 (1p) is one of the most characteristic changes in neuroblastomas (Brodeur et al., 1977 (Brodeur et al., , 1981 . 1p deletion is found in about 35% of all neuroblastomas and 70-80% of high-risk tumors (White et al., 1995 (White et al., , 2005 Attiyeh et al., 2005) , presumably representing loss of a tumor suppressor gene (TSG) from this region. The region deleted is usually quite large (1p32-1pter), and the break points are variable, but all tumors lose distal 1p. Using DNA-based polymorphisms, we have refined the region of consistent deletion to 1p36.31 (White et al., 1995 (White et al., , 2005 . Furthermore, we showed that microcell-mediated chromosome transfer of 1p into neuroblastoma cells suppressed transformation and tumorigenicity (Bader et al., 1991) . This suggests that a TSG is located at 1p36 and loss of this gene contributes to neuroblastoma development or progression.
Previously, we used microsatellite markers to map the smallest region of deletion (SRD) in 783 neuroblastomas and tumor-derived cell lines to 1p36.31 (White et al., 2005) . We narrowed the maximal SRD to between D1S2660 distally and D1S214 proximally, or about 2 Mb. This region is overlapped by the SRD identified by most other groups mapping 1p deletions in neuroblastomas (Schleiermacher et al., 1994; Takeda et al., 1994; Caron et al., 1995 Caron et al., , 2001 Cheng et al., 1995; Gehring et al., 1995; Martinsson et al., 1995 Martinsson et al., , 1997 Bauer et al., 2001) . Furthermore, the proximal and distal boundaries of our SRD on 1p36 were defined by two cases each, indicating that the region we defined contains at least one neuroblastoma TSG.
Here, we report two additional neuroblastomas with informative 1p36.31 deletions that further support our focus on this region. We have mapped 23 genes to the maximal SRD on 1p36.31. We have systematically analysed the coding regions of these genes for homozygous deletions and mutations in a panel of 30 neuroblastoma cell lines, but no consistent pattern of genetic change was identified. Further, we have analysed the expression of these 23 genes in a panel of 20 neuroblastoma cell lines with and without 1p deletion. Only nine of the genes show a low or absent pattern of expression in these lines, consistent with being a TSG. Based on the above information and their expression pattern in normal tissues (White et al., 2005) , as well as published information about the potential role of these genes in neuroblastoma pathogenesis, we have identified four genes as likely candidates for a 1p36 TSG, with CHD5 as the most attractive TSG candidate.
Results
We performed single nucleotide polymorphism (SNP) haplotype analysis of 430 primary neuroblastomas to identify allelic loss across the genome and found two cases with small informative deletions of 1p36. One case had a small terminal deletion, from the telomere to bp 6 912 889 proximally. The other had a small interstitial deletion from bp 3 844 939 distally to 26 101 519 proximally ( Figure 1 ). The SRD defined by these two cases (bp 3 844 939-6 912 889) corresponds closely to the SRD we had defined analysing 783 neuroblastomas with PCR-based polymorphisms (bp 4 704 484-6 884 577) (White et al., 2005) . Thus, our SRD is now defined by three cases at each end, thus providing a definitive localization of the 1p36.31 SRD to this region.
We identified 23 genes and 5 EST clusters in the SRD. Previously, we had identified 15 characterized genes, 9 uncharacterized genes and 6 EST clusters in the 2 Mb SRD (White et al., 2005) . Subsequent analysis by us and others now indicates that there are 23 characterized genes and 5 putative transcripts ( Figure 2 , Table 1 ). The uncharacterized transcripts in the SRD are C1orf211, Hs.12473, Hs.143963, Hs.250839 and Hs.156291, and there is currently no evidence that these transcripts encode proteins or have a biological function. To date, no microRNAs have been mapped within our SRD. Therefore, we focused on the 23 characterized genes for further mutation analysis and expression studies.
We developed primers and sequenced all coding exons, including splice donor/acceptor sites in both directions, of 20 candidate genes in 30 neuroblastoma cell lines (21 with 1p deletion) to determine if there was evidence of homozygous deletion or inactivation. We identified 64 previously described and novel SNPs. Forty were synonymous (silent) or had been previously described as naturally occurring genomic variations in dbSNP, and we found 11 more in a panel of 46 normal DNAs (previously undescribed polymorphisms, available on request). However, 13 were apparently acquired missense mutations or codon deletions involving 8 genes (Table 1 ). Previously, we had examined HKR3/ZBTB48 for mutations (Maris et al., 1997) , but none was found. The two remaining genes (FLJ10737/DNAJC11, CAMTA1) were examined for mutations in a recent report (Henrich et al., 2007 ), but only rare nonsynonymous mutations were found (Table 1) . Thus, there were no homozygous deletions, no nonsense or frameshift mutations and no pattern of mutational inactivation in the 23 genes in our SRD.
We used quantitative reverse transcription (RT)-PCR to assess the expression of these 23 genes in a panel of 20 neuroblastoma cell lines (15 with 1p deletion) compared to that observed in fetal brain (Table 2) . Thirteen genes were expressed at moderate levels (see Materials and methods) in virtually all cell lines, and there was no correlation with 1p deletion ( (Table 2) . We then focused on these nine genes because a TSG should have very low or absent expression in neuroblastomas, especially those with 1p36 deletion.
Previous expression analysis of these genes in normal tissues showed that five of the 23 genes (AJAP1, KCNAB2, CHD5, ACOT7 and CAMTA1) were preferentially expressed in the nervous system (White et al., 2005) . Although CAMTA1 had higher expression in neuroblastoma cell lines, the break point in the three cases defining our proximal boundary were either within the CAMTA1 coding region or just proximal to it. Combining the analysis of expression patterns in neuroblastoma cell lines and in normal tissues, AJAP1 and CHD5 appeared to be the strongest candidates. Other possible candidates based on expression and function included TNFRSF25 and CAMTA1, but TNFRSF25 did not have a neural pattern of expression, (White et al., 2005) . The 23 genes mapping within the maximal SRD are shown in order. The gene size and the intergenic distances are not representative. Shown at the bottom is a bracket representing the SRD defined by two informative cases analysed by SNP microarray genomic profiling described in this report. Henrich et al. (2007) .
Candidate TSGs from 1p36 in neuroblastomas ER Okawa et al and CAMTA1 had relatively high expression in the neuroblastoma cell lines.
Discussion
We have defined a common SRD on 1p36.31 in neuroblastomas. We previously analysed 783 neuroblastomas and narrowed the maximal SRD to a 2 Mb region from D1S2660 to D1S214 (White et al., 2005) . Martinsson et al. (1997) defined a larger region of deletion from D1S244 to the telomere in 68 neuroblastomas. Caron et al. (2001) defined two regions of terminal deletion: the smaller region is deleted in neuroblastomas without MYCN amplification, and the larger region is deleted in tumors with amplification. Their larger region entirely overlaps the smaller region. Takeda et al. (1994) made similar observations on 108 tumors using 14 polymorphic markers. Our SRD is entirely contained within both regions from both studies. Bauer et al. (2001) used PCR-based polymorphisms in 49 tumors to define a 1 Mb region. This region is proximal to ours with minimal overlap, but their distal boundary is defined by only one case. Finally, two groups have identified a 1p36 homozygous deletion in the NB-1 neuroblastoma cell line (Ohira et al., 2000; Chen et al., 2001) . However, this deletion is proximal to the SRD defined by us and most other groups, and it was not found in the primary tumor from which the cell line was derived. Thus, our SRD represents the most consistent SRD on 1p36 in neuroblastomas.
We have added two informative cases that further support the focus on our SRD. Our previous study of 783 neuroblastomas and tumor-derived cell lines (White et al., 2005) represents more cases analysed with more markers than any other reported series. Now, we have analysed 430 additional cases using an SNP-genotyping technique and have added two new informative cases that independently define an SRD that almost exactly overlaps the SRD defined above. Because the proximal and distal boundary of our SRD are now defined by three cases each, it is exceedingly likely that this region contains the TSG that is commonly deleted from 1p36 in neuroblastomas. We have identified 23 characterized genes in this region, so one of these genes is likely to be the neuroblastoma TSG.
Most genes in the SRD have never been associated with cancer pathogenesis. There is no published evidence to support a role for most genes in the region (Table 1) as TSGs in cancer generally, or neuroblastomas in particular. RPL22 recruits the EpsteinBarr early RNA and is linked to lymphoma associated with Epstein-Barr virus (Elia et al., 2004; Fok et al., 2006) . ICMT is an isoprenylcysteine methyltransferase that has been implicated in carcinogenesis and as a target for anticancer therapy (Bergo et al., 2004; WinterVann et al., 2005) . However, neither of these genes has been associated with neuroblastoma pathogenesis.
Five genes from the SRD have been investigated previously in neuroblastomas. The overlap between the SRD defined by us (White et al., 2005) and by Bauer et al. (2001) contained two genes: DNAJC11 and CAMTA1 (Katoh and Katoh, 2003; Henrich et al., 2006 Henrich et al., , 2007 . No mutations were found in either gene, and DNAJC11 expression was not associated with established prognostic variables or outcome. Low CAMTA1 expression was associated with unfavorable prognostic features and a poor outcome (Henrich et al., 2006) . We had analysed the sequence and expression of the transcription factor ZBTB48 (Maris et al., 1997), but we found no mutations, and expression was ubiquitous in normal tissues and neuroblastomas. TNFRSF25 is a death receptor that is deleted from 1p36 in oligodendrogliomas (Grenet et al., 1998; McDonald et al., 2005) , and low expression is associated with 1p deletion and MYCN amplification in neuroblastoma lines (Grenet et al., 1998; Eggert et al., 2002; McDonald et al., 2005) . Finally, we identified CHD5 on 1p36 and analysed its expression in neuroblastoma cell lines and primary tumors. We characterized CHD5 as a new member of a chromatin remodeling gene family with preferential expression in neural tissues and an inverse correlation with 1p deletion, consistent with a neuroblastoma TSG (Thompson et al., 2003) .
We found no evidence of homozygous deletion or inactivation of any of the 23 candidate genes. Here we sequenced all the coding regions of 20 genes in a panel of 30 neuroblastoma cell lines, 70% with 1p deletion. Because we were examining the single remaining allele in these latter cases, we were likely to find any homozygous deletion or inactivating mutation. Most mutations found were either silent mutations or previously described polymorphisms. None were nonsense mutations, and none were homozygous deletions or frameshift mutations. We detected rare, apparently acquired mutations in one or a few cell lines within 10 of the genes (Table 1) , but there was no significant frequency of mutational inactivation in any of the genes in our SRD. Previous reports by us and others had ruled out inactivating mutations in ZBTB48, DNAJC11 and CAMTA1 (Maris et al., 1997; Henrich et al., 2007) . Thus, all 23 genes within our SRD have been examined for mutations or homozygous inactivation, but none was found. This suggests that the second 'hit' for a TSG in this interval is most likely to be due to an epigenetic event, such as methylation, or that a functional effect is manifested through haploinsufficiency.
We analysed the expression of candidate TSGs in normal tissues and neuroblastoma cell lines. Previously, we had examined the expression of candidate TSGs from 1p36 in a panel of normal tissues, and most genes were ubiquitously expressed. Certain genes had more tissue-specific expression, and five had a restricted neural expression pattern (AJAP1, KCNAB2, CHD5, ACOT7 and CAMTA1). This pattern seemed suggestive of a neuroblastoma TSG but not definitive. Here we analysed the expression of the 23 genes in 20 neuroblastoma lines relative to fetal brain. The majority of genes were expressed in most cell lines at substantial levels. However, seven genes (AJAP1, HES3, GPR153, HES2, ESPN, TNFRSF25 and PLEKHG5) had very low expression (o10% of fetal brain) in all cell lines, and two genes (CHD5, RNF207) had virtually absent expression (o1% of fetal brain), which would be expected for a neuroblastoma TSG. Only AJAP1 and CHD5 had both restricted neural expression and low/ absent expression in neuroblastoma cell lines.
Based on this information, we narrowed down the likely candidates for the 1p36 TSG in neuroblastomas. Of the nine genes with low/absent expression in neuroblastomas, seven have never been implicated in human neoplasia (AJAP1, RNF207, HES3, GPR153, HES2, ESPN and PLEKHG5). However, AJAP1 shows preferential neural expression, so it remains a potential candidate. TNFRSF25 shows low expression in neuroblastoma lines with 1p deletion and MYCN amplification (Eggert et al., 2002) , and its function is consistent with a TSG. Finally, CHD5 shows preferential neural expression, low expression in neuroblastoma cell lines, a correlation with 1p deletion in tumors and a putative function consistent with a TSG (Thompson et al., 2003) . CAMTA1 was the only gene with higher expression in neuroblastoma cell lines that had been implicated in neuroblastoma or correlated with risk factors or outcome, and it was near the proximal break points.
We conclude that CHD5, TNFRSF25, CAMTA1 and AJAP1 are the most promising candidate TSGs, but CHD5 is the strongest. Its expression is virtually absent in neuroblastoma cell lines, and it has preferential expression in neural tissues. There is an inverse correlation of CHD5 expression with 1p deletion, consistent with a neuroblastoma TSG (Thompson et al., 2003) . Each of the other genes lacks at least one of these features, but they cannot be entirely ruled out based on current information. Therefore, we are continuing to characterize these four genes and assess their expression and function in primary neuroblastomas and cell lines.
Note added in proof While our manuscript was under review, Bagchi et al. (2007) published a paper describing CHD5 as a TSG using chromosome engineering to generate mouse models with gain and loss of a region corresponding to human 1p36 that contained mCHD5. This approach functionally identified mCHD5 as a TSG that controls proliferation, apoptosis and senescence via the p19Arf/ p53 pathway. Their results also suggest that gene dosage is tightly regulated and that homozygous deletion of mCHD5 is rare, consistent with our findings with hCHD5 in human neuroblastomas. Their independent identification of mCHD5 as a TSG further validates our findings in neuroblastoma and suggests that CHD5 may play a role in the pathogenesis of other human cancers characterized by 1p36 deletions.
Materials and methods

Neuroblastoma cell lines
We examined candidate TSG expression in 20 neuroblastoma cell lines. This included 4 lines without 1p deletion (NBL-S, SKNFI, SKNSH and SKNDZ), 1 line with rearrangement but no apparent deletion (NGP), 3 lines with 1p deletion and no MYCN amplification (NB69, LAN-6 and SKNAS) and 12 lines with 1p deletion and MYCN amplification (CHP134, CHP901, CHP902R, IMR5, KCN, KCNR, LAN-1, LAN-5, NLF, NMB, SKNBE2 and SMS-KAN) (Thompson et al., 2001; White et al., 2005) .
High-density SNP haplotype mapping
We used the Illumina Sentrix HumanHap550 whole genome SNP Array platform (Gunderson et al., 2005) to detect genome-wide DNA aberrations in a panel of 430 neuroblastomas with matched blood. The assay is highly accurate and reproducible, with overall call rates of 99.94% and excellent concordance with HapMap data (Steemers et al., 2006) . The SNP assays were chosen from a combination of exon-centric, highly conserved and putative functional SNPs located directly within coding, promoter, and highly conserved noncoding regions. This platform allows for simultaneous measurement of both intensity differences and allelic ratios, making it possible to assess both DNA copy number and copy-neutral loss of heterozygosity, and detects chromosomal aberrations in samples bearing constitutional deletions as well as in tumor samples (Oliphant et al., 2002) .
Primers and probes
Gene-specific primers and fluorescent probes were purchased from Applied Biosystems' (AB, Foster City, CA, USA) TaqMan Assays-on-Demand service for the following genes:  AJAP1, NPHP4, KCNAB2, CHD5, RNF207, C1orf188,  ICMT, GPR153, ACOT7, HES2, ESPN, TNFRSF25,  PLEKHG5, NOL9, TAS1R1, ZZBTB48, KLHL21, PHF13 and THAP3 (AB). For the genes RPL22 and HES3, as well as C1orf211, Hs.12473, Hs.243963, Hs.250839 and Hs.156291, primers and probes were designed using Primer Express software (AB). The PCR primers and probes used for these genes are available upon request.
DNA and RNA isolation from neuroblastoma cell lines Genomic DNA was isolated from neuroblastoma lines using Qiagen's DNeasy kit according to the manufacturer's instructions (Qiagen Inc., Valencia, CA, USA). Total RNA was extracted from cell lines using Qiagen's RNeasy system. A panel of mRNAs derived from 17 normal tissues was purchased from Clontech (Clontech Labs, Mountain View, CA, USA). RNA from cell lines and tissues was used as a template for cDNA synthesis using the AB High Capacity cDNA Archive kit.
Real-time PCR assay
Expression levels of each gene were evaluated by real-time RT-PCR using the ABI 7900HT Real-Time PCR system as described previously (Ho et al., 2005) . Each reaction was run in triplicate, and we generated a standard curve for each probe using serial dilutions from reference cDNA to quantitate relative gene expression. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as an endogenous reference, and each sample was normalized to its GAPDH content.
Mutation analysis by direct sequencing
We analysed a panel of 30 neuroblastoma cell lines and primary tumors for sequence alterations in the following genes: AJAP1, NPHP4, KCNAB2, CHD5, RPL22, RNF207, C1orf188, ICMT, HES3, GPR153, ACOT7, HES2, ESPN, TNFRSF25, PLEKHG5, NOL9, TAS1R1, KLHL21, PHF13 and THAP3. Coding regions for GPR153, CHD5, NPHP4 and AJAP1 were screened by single strand conformational polymorphism (SSCP) either with genomic-PCR or RT-PCR products. Subsequently, all shifted bands detected on gel electrophoresis were directly sequenced from genomic DNA. For the remaining genes, we performed direct exon sequencing of their coding regions and immediate exon-intron boundaries, using genomic DNA. Primers were designed using Primer3 software (Rozen and Skaletsky, 2000) . All PCR products were sequenced bidirectionally using the BigDye Terminator v3.1 Cycle Sequencing Kit and an Applied Biosystem's 3730 DNA Analyzer. Analysis of our sequences for variations was performed using the programs Phred, Phrap and Consed (Buetow et al., 1999) . Two investigators independently analysed the sequences, and discrepancies were either resequenced or reanalysed. Variants found in the sequenced products were investigated in dbSNP. Those not found within this database were further investigated in a panel of normal genomic DNA samples (SNP500V panel of 102 lymphoblastoid cell lines; Coriell Institute, Camden, NJ, USA).
Statistical analysis
The expression level relative to fetal brain or brain was used to examine the patterns of expression for 23 genes in 20 neuroblastoma cell lines. For each gene, if the 75th percentile gene expression in the cell lines was below 10% the level in fetal brain, the gene was grouped in the very low gene expression category. If the 75th percentile was less than 1% of fetal brain, it was considered virtually absent. Otherwise, the gene was considered in the moderate/high expression category (18-310% of fetal brain). Within each gene, two sample t-tests were used to examine the relation between gene expression and 1p status. Wilcoxon rank-sum test was used to confirm the results of t-test if there was marginal significant in t-test (Po0.1).
